6/28/23, 12:27 AM Ciprofloxacin for 7 vs. 14 days in pyelonephritis Pathway Feedback Search Clinical Topics Home Studies Ciprofloxacin for 7 vs. 14 days in pyelonephritis Ciprofloxacin for 7 vs. 14 days in pyelonephritis Disease Acute pyelonephritis Trial question Is ciprofloxacin for 7 days noninferior to 14 days ciprofloxacin in women with acute pyelonephritis? Study design Multi-center Double blinded RCT Population 248 female patients Inclusion criteria: non-pregnant women with acute pyelonephritis Key exclusion criteria: pregnancy or lactation; inadequate contraception for women of childbearing age; known hypersensitivity to fluoroquinolones; systemic antibiotic treatment within the preceding 72 h; presence of an indwelling urinary catheter or clean intermittent catheterization of the bladder Interventions N=126 treatment with ciprofloxacin for 7 days (500 mg BID for 7 days followed by placebo for next 7 days) N=122 treatment with ciprofloxacin for 14 days (500 mg BID for 14 days) Primary outcome Short-term clinical cure 97.0 % 97 96 72.8 % 48.5 % Difference not exceeding nonferiority margin 24.3 % 0.0 % Treatment with ciprofloxacin for 7 days Treatment with ciprofloxacin for 14 days https://web.pathway.md/studies/recj3Zfhpvw35fTnd 1/2 6/28/23, 12:27 AM Ciprofloxacin for 7 vs. 14 days in pyelonephritis Pathway Difference not exceeding nonferiority margin in short-term clinical cure (97% vs. 96%; ARD -0.9, 90% CI -6.5 to 4.8) Safety outcomes No significant difference in adverse events (5% vs. 6%). Significant differences in mucosal candida infection (0 vs. 5, p = 0.036). Conclusion In non-pregnant women with acute pyelonephritis, treatment with ciprofloxacin for 7 days were noninferior to treatment with ciprofloxacin for 14 days with respect to a short-term clinical cure. Reference Sandberg T, Skoog G, Hermansson AB et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non- inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90. Open reference URL https://web.pathway.md/studies/recj3Zfhpvw35fTnd 2/2